Equities analysts expect that MAXIMUS, Inc. (NYSE:MMS) will post $617.67 million in sales for the current quarter, according to Zacks. Five analysts have made estimates for MAXIMUS’s earnings, with the lowest sales estimate coming in at $611.80 million and the highest estimate coming in at $622.79 million. MAXIMUS posted sales of $622.05 million during the same quarter last year, which would indicate a negative year-over-year growth rate of 0.7%. The company is scheduled to announce its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that MAXIMUS will report full-year sales of $617.67 million for the current year, with estimates ranging from $2.48 billion to $2.50 billion. For the next year, analysts anticipate that the firm will post sales of $2.61 billion per share, with estimates ranging from $2.59 billion to $2.63 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that cover MAXIMUS.
MAXIMUS (NYSE:MMS) last issued its quarterly earnings data on Thursday, February 8th. The health services provider reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.01. MAXIMUS had a net margin of 8.99% and a return on equity of 22.93%. The business had revenue of $623.10 million for the quarter, compared to analyst estimates of $624.36 million. During the same period last year, the business posted $0.71 earnings per share. The firm’s quarterly revenue was up 2.6% on a year-over-year basis.
Shares of MAXIMUS (NYSE:MMS) opened at $67.97 on Wednesday. MAXIMUS has a twelve month low of $57.12 and a twelve month high of $72.71. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.01. The company has a market cap of $4,448.23, a price-to-earnings ratio of 20.23, a P/E/G ratio of 2.27 and a beta of 1.18.
The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Investors of record on Thursday, February 15th were given a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date was Wednesday, February 14th. MAXIMUS’s dividend payout ratio (DPR) is currently 5.36%.
In related news, insider Mark Andrekovich sold 2,700 shares of the firm’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $72.00, for a total value of $194,400.00. Following the completion of the transaction, the insider now owns 20,296 shares of the company’s stock, valued at $1,461,312. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, General Counsel David Francis sold 3,600 shares of the firm’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $64.50, for a total transaction of $232,200.00. Following the completion of the transaction, the general counsel now directly owns 10,017 shares of the company’s stock, valued at approximately $646,096.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,300 shares of company stock valued at $3,209,230. 2.48% of the stock is owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in MMS. Amundi Pioneer Asset Management Inc. bought a new position in MAXIMUS in the fourth quarter valued at $163,000. Steward Partners Investment Advisory LLC bought a new position in MAXIMUS in the fourth quarter valued at $169,000. Capital One National Association bought a new position in MAXIMUS in the fourth quarter valued at $213,000. Zeke Capital Advisors LLC bought a new position in MAXIMUS in the fourth quarter valued at $222,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in MAXIMUS by 51.3% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,581 shares of the health services provider’s stock valued at $256,000 after purchasing an additional 1,214 shares in the last quarter. 96.72% of the stock is owned by institutional investors and hedge funds.
MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MAXIMUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MAXIMUS and related companies with MarketBeat.com's FREE daily email newsletter.